在多发性骨髓瘤中选择最佳的维持策略
Benjamin Puliafito1, Diana Cirstea1, Noopur Raje1
1Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA.
多发性骨髓瘤的维护策略正在超越莱纳利多米德的发展. 新的方法,包括蛋白酶体抑制剂和抗CD38单克隆抗体 (mAbs),提供了增强的益处,特别是在高风险患者.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 列纳利多米德是用于多发性骨髓瘤自主干细胞移植后的标准维护疗法.
- 高风险多发性骨髓瘤患者可能从风险适应的维护策略中受益.
- 反CD38单克隆抗体 (mAbs) 越来越多地用于诱导和巩固疗法.
研究的目的:
- 审查多发性骨髓瘤的维护策略的不断变化的格局.
- 探索蛋白质酶抑制剂和抗CD38 mAbs在维持治疗中的作用.
- 讨论未来的方向,包括免疫疗法和最小残留疾病引导方法.
主要方法:
- 对多发性骨髓瘤维持疗法的当前文献和临床实践的审查.
- 对新兴药物和治疗模式的新兴数据的分析.
- 讨论正在进行的免疫治疗方法和MRD指导策略的研究.
主要成果:
- 结合蛋白酶体抑制剂的风险适应策略对于高风险患者来说是有前途的.
- 抗CD38mAbs正在考虑作为维持疗法,改变治疗范式.
- 新型免疫疗法和以最小残留疾病 (MRD) 为指导的策略正在积极研究中.
结论:
- 多发性骨髓瘤的维持疗法正在转向更加动态和个性化的方法.
- 未来的战略旨在采取更有效,更持久的应对措施,并有可能降低局势的升级.
- 新型药物和MRD监测的整合将完善未来的维护协议.
更多相关视频
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
相关概念视频
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Chronic Kidney Disease IV: Nursing Management
Myocarditis IV: Nursing Management
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
